NIBEC
June 22, 2026
Theater 4
Type: Company Presentation
Focus Area:
Multiple Therapeutics
NIBEC is a pioneering biotechnology company dedicated to developing peptide-based, next-generation therapeutics for fibrosis, obesity, and oncology. Powered by our proprietary AI-assisted TOPscovery platform, we efficiently discover and advance novel drug candidates to address severe unmet medical needs. Our pipeline features three standout assets: Peptide therapeutics including NP-201-401, clinical therapeutic that have demonstrated exceptional epithelial regeneration at fibrotic disease sites; Regenotide, a novel anti-obesity candidate delivering unique triple activity by increasing muscle mass, reducing fat accumulation, and treating associated MASH; and NP-501, a selective renal carcinoma treatment showing significant tumor growth inhibition with strong potential for synergy in combination with immune checkpoint inhibitors. At BIO 2026, we are actively seeking strategic collaborations and licensing opportunities to co-develop our transformative portfolio globally.
Company HQ City:
Seoul
Company HQ State:
Seoul
Company HQ Country:
Korea, Republic of
Year Founded:
2004
Lead Product in Development:
Peptide therapeutics 1) Regenotide for obesity 2) NP201-401 for fibrosis 3) NP-501 for Oncology
CEO
Prof.Dr. Chong Pyung Chung
Development Phase of Lead Product
Phase II
Exchange
KRX
Ticker
KRX 138610
When you expect your next catalyst update?
We anticipate our next wave of major catalyst updates as first half of 2027.
What is your next catalyst (value inflection) update?
Our next major catalysts are centered around clinical advancements and strategic global partnering for our lead assets. For NP-201, our core anti-fibrotic program, the primary catalyst is the upcoming initiation of Phase 2 clinical trials, supported by our exceptional preclinical data in epithelial regeneration. For Regenotide, our triple-action obesity/MASH asset, we are rapidly advancing toward IND-enabling studies and finalizing optimized formulations. Concurrently, a continuous catalyst is our active negotiation for global out-licensing and strategic co-development partnerships for both our therapeutics and our proprietary AI-driven TOPscovery platform."
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}